株式会社ヘリオス

Healios is at the forefront of the rapidly evolving regenerative medicine field, pioneering the research and development of somatic stem cell and iPSC regenerative medicines. Listed on the TSE Mothers in June 2015, Healios is dedicated to delivering hope and innovative treatment methods to patients worldwide. Healios is committed to advancing the development and manufacture of regenerative and cellular medicines on a global scale.

With its primary address at 2-4-1 Hamamatsucho, Minato-ku, Tokyo 105-6115, JP, and an additional location at 1-5-2 Minatojima-Minamimachi, Chuo-ku, Kobe, Hyogo 650-0047, JP, Healios operates with a global perspective, aiming to transform the landscape of healthcare through biotechnology. The company's focus on regenerative medicine positions it as a key player in addressing unmet medical needs and improving patient outcomes.

Healios strives to provide advanced treatment options to those in need. Healios is actively shaping the future of healthcare. We invite the manager of Healios to create a customized and exclusive company showcase and product listing on our platform.